

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 16:21:12 +0000
To: Hahn, Stephen
Cc: Redfield, Robert R. (CDC/OD);r (b) (6);Cassetti, Cristina (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]; (b) (6);Conrad, Patricia (NIH/NIAID) [E];Graham, Barney (NIH/VRC) [E];Mascola, John (NIH/VRC) [E];Lerner, Andrea (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Coronavirus test
Attachments: nCoV-ColorimetricLAMP.pdf

Steve:

Let us discuss this when we are together at the 4:00 PM TF meeting.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Roberts, Rich <(b) (6)>
Sent: Tuesday, March 10, 2020 12:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus test

Dear Tony:

If you can find a few minutes, I would very much like to talk with you briefly about a new diagnostic LAMP test for coronavirus COVID-19 that we have developed here at NEB. I attach a paper now in the MedRxiv that briefly describes the test. It has been used already in Wuhan and because of its simplicity, speed and visual output we think it would be very useful for use here in the US. We have just met with several people at Mass General Hospital and will be working with them for local validation here in MA. The test itself is very inexpensive, does not require any special equipment nor training of technicians. This would appear ideal for the FDA and the CDC to know about, but I have not so far been able to reach